Zobrazeno 1 - 10
of 18
pro vyhledávání: '"MA Alcácera López"'
Autor:
R Fresquet Molina, JM Vinuesa Hernando, M Zurera Berjaga, Mercedes Gimeno, I Varela Martínez, MA Alcácera López, P Gómez Rivas, R Gracia Piquer
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance The inhibitor of cyclin dependent kinases 4 and 6, palbociclib, was a major advance in the treatment of metastatic breast cancer. Aim and objectives To describe the effectiveness and incidence of neutropenia with palbociclib
Autor:
JM Vinuesa Hernando, M. J. Crusells Canales, I. Sanjoaquin Conde, M Gimeno Gracia, MA Alcácera López, A Frutos Perez-Surio, R Gracia Piquer, S Malo Fumanal, S. Letona Carbajo
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance The effectiveness of current antiretroviral treatments has prolonged the survival of HIV patients, and with age, the prevalence of comorbidities increases. The new clinical conditions of these patients may cause potentially
Autor:
MJ Nebot Villacampa, MA Alcácera López, JM Vinuesa Hernando, I Varela Martínez, R Gracia Piquer, T Salvador Gómez, M. Arenere Mendoza, R Fresquet Molina, FJ Campos Montellano, M Galindo Allueva
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Since the first biosimilar drug was authorised, medicine agencies have promoted their use. However, interchangeability or switching are different in each country, creating disparity in their use. Aim and objectives To measur
Autor:
T Salvador Gómez, R Fresquet Molina, O Horna Oreja, MA Alcácera López, M Gimeno Gracia, JM Vinuesa Hernando, A Frutos Perez-Surio, R Gracia Piquer, FJ Campos Montellano, M Galindo Allueva
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Adalimumab and etanercept are two of the most used biologic drugs worldwide in a variety of chronic diseases. The introduction of biosimilar drugs (BS) for both has revolutionised the market and may enable more patients to a
Autor:
Pérez-Surio, Alberto Frutos, Gimeno-Gracia, Mercedes, Ma. Alcácera López, Ma. Sagredo Samanes, Ma. Pardo Jario, Ma. Salvador Gómez
Search strategy. (DOCX 11 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40a8544c2b4c2884a4efb045954d686f
Autor:
MA Alcácera López, S Gamarra Calvo, E Fernández Alonso, MJ Crusells Canales, M Gimeno Gracia, G Verdejo Muñoz
Publikováno v:
Clinical pharmacy.
Background Boosted protease inhibitor monotherapy may offer antiviral efficacy while reducing drug interactions, costs and toxicity in HIV infected patients. Purpose The aim of this study was to assess the efficacy of darunavir/ritonavir (DRV/r) mo
Autor:
MA Alcácera López, MJ Cumbraos Sánchez, A Frutos Perez-Surio, B Bonaga Serrano, I Puértolas Tena, E Fernández Alonso, V Compaired Turlán, MA Sagredo Samanes
Publikováno v:
Clinical pharmacy.
Background Trastuzumab containing regimens are the standard of care for HER2+ breast cancer. While intravenous trastuzumab (Tiv) is administered as a weight based dose using an initial 90 min infusion followed by a subsequent 30 min infusion, subcuta
Autor:
MA Alcácera López, S Gamarra Calvo, MJCumbraos Sánchez, I Puértolas Tena, B Abad Bañuelos, O Horna Oreja, MPPardo Jario, V Compaired Turlán
Publikováno v:
Clinical pharmacy.
Background Currently, immunotherapy is a very active area of oncology research. It is a treatment that uses the body’s own natural defences to kill cancer cells. New immunotherapy drugs are showing significant and extended effectiveness, but they a
Autor:
E Fernández Alonso, M.A. Allende Bandrés, M Gimeno Gracia, T Salvador Gómez, I Puértolas Tena, M Merchante Andreu, MA Alcácera López, Y Lanza Salcines, B Bonaga Serrano
Publikováno v:
European Journal of Hospital Pharmacy. 23:A164.2-A164
Background The dispensation of enteral nutrition (EN) to institutionalised patients has recently being carried from the hospital pharmacy services corresponding to the health area. Hospital pharmacists can provide the development of pharmaceutical ca
Autor:
B Bonaga Serrano, MA Alcácera López, B Abad Bañuelos, I Puértolas Tena, B Amores Arriaga, M Merchante Andreu, T Salvador Gómez, E Guarc Prades, M Gimeno Gracia
Publikováno v:
European Journal of Hospital Pharmacy. 23:A241.2-A242
Background The emergency departments have operating characteristics that make them especially prone to the occurrence of medication errors (ME). These units represent one of the departments with the highest incidence of errors with serious outcomes.